Nuoqiao Pharmaceuticals

Nuoqiao Pharmaceuticals is a Shanghai-based biotechnology company specializing in the discovery and development of innovative small molecule therapeutics for oncology and metabolic diseases. Founded in 2017 by industry veterans, the company leverages an integrated R&D platform that combines medicinal chemistry, structural biology, and pharmacology to accelerate drug candidate identification. Its lead clinical program, NQ-101, is a highly selective inhibitor of Ubiquitin carboxyl-terminal hydrolase 1 (USP1) currently undergoing Phase 1 trials for the treatment of advanced solid tumors. In addition to its internal pipeline, Nuoqiao provides high-end contract research services to global pharmaceutical partners, focusing on lead optimization and preclinical development. The company is backed by prominent investors including Qiming Venture Partners and TF Capital, positioning it as a rising player in the Chinese biotech ecosystem.